Merck's Q3 2010 earnings call highlighted continued strong performance despite economic headwinds, driven by key brands like Januvia, Janumet, Singulair, and Remicade.  Management expressed confidence in the company's future, emphasizing the robust pipeline and strategic investments, especially in emerging markets.  The call also noted the company's continued progress in achieving merger synergies and managing expenses. This suggests a positive short-term outlook, potentially leading to stock price appreciation.
[1]
